Klaria Interim Report

Initiated large-scale production of KL-00119 oral film (sumatriptan) for upcoming registration study

THIRD QUARTER OF 2019

∞ Net sales amounted to 0.1 MSEK (0.0 MSEK)

∞ R&D costs for the period amounted to 5.4 MSEK (4.6 MSEK)

∞ Profit after tax amounted to -7.2 MSEK (-6.1 MSEK)

∞ Earnings per share for the quarter amounted to -0.23 SEK (-0.20 SEK)

∞ Cash flow from operating activities amounted to -5.5 MSEK (-3.2 MSEK)

∞ Cash and cash equivalents on the balance day amounted to 8.9 MSEK (5.1 MSEK)

∞ Shareholder’s equity per September 30, 2019 amounted to 87.5 MSEK (102.8 MSEK)